Author

About BioPact

This author has not yet filled in any details.
So far BioPact has created 4 entries.

BIOPACT’S MGMR® DRUG DELIVERY TECHNOLOGY SUCCEEDS IN MITIGATING SIDE EFFECTS OF DOXORUBICIN WHILE RETAINING ANTI-CANCER EFFICACY IN LYMPHOMA AND METASTASIS MOUSE MODELS

Austin, TX (June 13, 2017) BioPact’s nanodelivery technology produced in vivo evidence that the carbon nanotube-based drug delivery system, Medical-Grade MOLECULAR REBAR® (MGMR®), successfully treated two forms of cancer while reducing the side effects of the API in this study, Doxorubicin. The studies were conducted at Charles River Laboratories and utilized two orthotopic cancer […]

By |June 13th, 2017|News|0 Comments

BIOPACT’S CO-FOUNDER RESUMES ROLE AS CHIEF EXECUTIVE OFFICER

Austin, TX (May 9th, 2017) BioPact’s co-founder, Kent Phelps, has resumed his role as CEO effective immediately. After 20 years of practicing law, Kent launched BioPact in 2014 with co-founder and lead investor Randy Kinsel.  BioPact was later established as a joint venture with the inventors of Molecular Rebar®, Kurt Swogger and Dr. […]

By |May 11th, 2017|News|0 Comments

BIOPACT’S MGMR® DRUG DELIVERY TECHNOLOGY SUCCEEDS IN TRANSPORTING CELL IMPERMEABLE PEPTIDES ACROSS CELL MEMBRANE TRIGGERING 100% CANCER CELL DEATH

Austin, TX (March 9, 2017) BioPact’s nanodelivery technology, MGMR®, demonstrated highly efficacious intracellular delivery of KLAKLAK, a pro-apoptotic peptide known to be cell membrane impermeable. When loaded on MGMR, KLAKLAK crossed the cell membrane of LNCaP human prostate cancer cells, triggering apoptosis in 100% of the cells in repeated studies.

KLAKLAK is a 1.5kD peptide […]

By |March 10th, 2017|News|0 Comments

BIOPACT ANNOUNCES MAXIMUM TOLERATED DOSE STUDY RESULTS FOR ITS MEDICAL GRADE MOLECULAR REBAR (MGMR®) NANOTECHNOLOGY

Cambridge, MA- (May 10, 2016) BioPact announced tolerability assessment data of its MGMR® (Medical Grade Molecular Rebar) nanotechnology. Study results indicated the maximum tolerated dose of MGMR is 180% higher than the therapeutically significant dose that was used in its previous successful safety study. Secondary endpoints indicated that multiple daily dosing was deemed well […]

By |May 11th, 2016|News|0 Comments